FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Randomized, double-blind treatment withdrawal or continuation with ruxolitinib cream in vitiligo: findings from the Topical Ruxolitinib Evaluation in Vitiligo (TRuE-V) long-term extension phase III study. PMID 41453117 · Br J Dermatol · 2026-Apr-17 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Experiences of Migraine and Erenumab Treatment in Japan: Qualitative Interviews with Clinical Trial Participants. PMID 41991782 · Patient · 2026-Apr-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy. PMID 42003280 · Cancer · 2026-Apr-15 The study is a Phase 2 randomized trial in oncology patients with a drug intervention, but it does not meet the definitive phase requirement (Phase III/IIIb or Phase II/III) and does not report a time-to-event efficacy endpoint, which are required for inclusion. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Belantamab mafodotin, bortezomib, and dexamethasone for RRMM in the Japan expansion cohort of the phase 3 DREAMM-7 trial. PMID 41986580 · Int J Hematol · 2026-Apr-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Preoperative Radiotherapy and Postoperative Complications Among Patients with Primary Retroperitoneal Sarcoma: A Post Hoc Analysis of the EORTC-62092 (STRASS) Phase 3 Randomized Clinical Trial. PMID 41983724 · Ann Surg · 2026-Apr-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Olopatadine plus mometasone for seasonal allergic rhinitis treatment: A pooled analysis of clinical trials. PMID 41985293 · Braz J Otorhinolaryngol · 2026-Apr-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Developing Transdiagnostic Single-Session Interventions for University Students Experiencing Disordered Eating: A Mixed-Method Co-Design Study. PMID 41978984 · Int J Eat Disord · 2026-Apr-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma. PMID 42074119 · Int J Mol Sci · 2026-Apr-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and Safety of a Full-Dose Regimen of Cell Culture-Derived Quadrivalent Inactivated Influenza Vaccine in Children Aged 6-35 Months: Results from a Multinational Phase 3 Randomised Controlled Trial. PMID 42042817 · Vaccines (Basel) · 2026-Apr-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of co-administration of adjuvanted respiratory syncytial virus prefusion F protein vaccine with 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: a randomized, non-inferiority trial. PMID 41994955 · Clin Infect Dis · 2026-Apr-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma. PMID 42135107 · Clin Genitourin Cancer · 2026-Apr-12 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Newer Therapeutics to Selectively Kill Clostridioides difficile and Restore the Microbiome. PMID 42042323 · Infect Dis Rep · 2026-Apr-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Annual immunogenicity measurements in randomized clinical trials help reveal heterogeneity in long-term vaccine efficacy: a pooled logistic regression modeling study. PMID 41793964 · Vaccine · 2026-Apr-11 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: long-term efficacy and safety through 5 years in the SELECT-EARLY study. PMID 41967478 · Mod Rheumatol · 2026-Apr-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 study results for oral PCSK9 inhibition with enlicitide. PMID 41966715 · Med · 2026-Apr-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study. PMID 41961227 · Jpn J Ophthalmol · 2026-Apr-10 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials. PMID 41791006 · J Clin Oncol · 2026-Apr-10 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
S
B
|
严格 v3 独有 | eligiblephase3_publication_type | confirmed 2 Figure · 7 Panel · risk visible |
| Bayesian adaptive randomization in the I-SPY2 sequential multiple assignment randomized trial. PMID 42053379 · Biometrics · 2026-Apr-09 The record describes the I-SPY2 SMART as a Phase 2 platform trial, not Phase III/IIIb. It is a methodology paper presenting a Bayesian adaptive randomization scheme, not a primary report of trial results with a time-to-event efficacy endpoint. The primary endpoint is pathological complete response (pCR), which is not a time-to-event outcome (OS, PFS, DFS, etc.). The intervention involves novel agents, but the paper focuses on the trial design and randomization algorithm, not on reporting specific drug intervention efficacy results. Therefore, it fails multiple key eligibility criteria: it is not a Phase III trial, lacks a time-to-event endpoint, is not a drug intervention efficacy result report, and is not an original formal trial result. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial. PMID 41966308 · J Hepatol · 2026-Apr-09 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Function-preserving radical surgery for early-stage non-small cell lung cancer: A review of limited resection approaches. PMID 41642077 · Jpn J Clin Oncol · 2026-Apr-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Bayesian reanalysis to assess consistency of TALAPRO-2 results in the Japanese subgroup with metastatic castration-resistant prostate cancer. PMID 41543049 · Jpn J Clin Oncol · 2026-Apr-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Multicenter, Randomized, Double-Masked, Sham-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-on Corneal Crosslinking in Keratoconus Subjects 8 to 45 Years of Age: Baseline Endothelial Studies. PMID 41960981 · Cornea · 2026-Apr-08 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE Trials. PMID 41956912 · Eur Urol Oncol · 2026-Apr-08 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. PMID 41955533 · J Clin Endocrinol Metab · 2026-Apr-07 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 h without thrombectomy-A secondary analysis of the TRACE-III randomized trial. PMID 41944559 · Int J Stroke · 2026-Apr-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| SKYSCRAPER-02C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage SCLC in China. PMID 41950998 · J Thorac Oncol · 2026-Apr-06 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B. PMID 41945711 · Hepatology · 2026-Apr-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. PMID 41937088 · Ann Oncol · 2026-Apr-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial. PMID 41934626 · J Natl Cancer Inst · 2026-Apr-03 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Megestrol acetate versus dexamethasone to prevent nausea and vomiting in patients with gastric or gastro-oesophageal junction cancer treated with oxaliplatin-based chemotherapy: study protocol of a multicentre, randomised, non-inferiority trial. PMID 41932699 · BMJ Open · 2026-Apr-03 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Re: Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin-naïve Non-muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301). PMID 41934038 · Eur Urol · 2026-Apr-02 The record is a letter to the editor responding to a previously published trial report. The title explicitly states 'Re:', and no abstract is provided to verify the necessary inclusion criteria. Therefore, it is not an original formal result report of a randomized trial. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Subarachnoid Hemorrhage: Clazosentan vs. Fasudil for Vasospasm Prevention (SAVIOR) Study: Study Protocol for a Prospective, Multicenter, Randomized Trial. PMID 41927991 · Neurocrit Care · 2026-Apr-02 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. PMID 41346230 · Blood · 2026-Apr-02 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 1 Panel · risk visible |
| The Prognostic Impact of Supraclavicular Lymph Node Metastases in Lung Cancer: Do We Need a Modification of the Current Staging System? PMID 41945947 · Asian Pac J Cancer Prev · 2026-Apr-01 This is a retrospective observational study of Stage IIIB NSCLC patients receiving chemoradiation therapy. It is not a randomized trial, does not specify a drug-containing intervention, and is not a Phase III/IIIb or Phase II/III trial. It is a prognostic analysis with time-to-event endpoints (PFS, OS), but does not meet the eligibility criteria for a randomized drug trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients: The Phase 2 MARBLE Randomized Clinical Trial. PMID 41931297 · JAMA Netw Open · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis. PMID 41811770 · Eur J Gastroenterol Hepatol · 2026-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Phase 2b trial of inhaled imatinib for treatment of pulmonary arterial hypertension. PMID 41738079 · Am J Respir Crit Care Med · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. PMID 41697690 · JAMA Neurol · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Correction to: Randomized, Double-Blind, Active-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Zastaprazan Compared to Esomeprazole in Erosive Esophagitis. PMID 41556513 · Am J Gastroenterol · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Vitamin D for tuberculosis or acute respiratory infections: lost in translation? PMID 41549871 · Curr Opin Infect Dis · 2026-Apr-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials. PMID 41500250 · J Natl Cancer Inst · 2026-Apr-01 This is an individual patient data meta-analysis of multiple RCTs, not a primary report of a single trial with a drug intervention. While it analyzes phase III trials, it is a secondary analysis, and the original trials are not individually reported here with their drug-specific results. The study focuses on statistical methodology (conditional survival) rather than reporting the efficacy of a specific drug intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Validity and Psychometric Properties of 3 and 4 Visual Analog Scale in Participants With Psoriatic Arthritis Treated With Guselkumab. PMID 41326161 · J Rheumatol · 2026-Apr-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies. PMID 41195829 · Int J Cancer · 2026-Apr-01 The record describes a meta-analytic study examining the exclusion of patients with renal impairment from phase 3 RCTs in hematologic malignancies. While it is oncology, human, randomized, phase 3, and involves drug interventions, it is not an original result report of a single trial. It lacks a primary time-to-event efficacy endpoint, as its outcomes are about trial design (eligibility criteria), not patient outcomes like OS or PFS. Therefore, it is excluded. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Design and implementation of interventions to improve sexual health of women with endometriosis: A mixed-methods study protocol with an interventional design. PMID 42312110 · Int J Reprod Biomed · 2026-Apr 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature. PMID 42229011 · Cancer Radiother · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. PMID 42181314 · Cureus · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Strengthening self-continuity to reduce depressive symptoms and derailment: A multiphasic mixed-methods randomized controlled trial. PMID 42080860 · J Consult Clin Psychol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of gepotidacin versus standard of-care antibiotics for the treatment of uncomplicated urogenital infections in adults and adolescents: a systematic review and meta-analysis. PMID 42047482 · Expert Rev Anti Infect Ther · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of Once-Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants. PMID 42023995 · J Clin Pharmacol · 2026-Apr The record describes a Phase I pharmacokinetic study in healthy volunteers for pulmonary arterial hypertension, not an oncology trial. It lacks a time-to-event efficacy endpoint and is not a definitive randomized trial in cancer patients. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Addition of immune checkpoint inhibitors to intravesical BCG for high-risk BCG-naïve non-muscle invasive bladder cancer: Systematic review and meta-analysis. PMID 42022227 · BJUI Compass · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |